Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Xuan Li*, Elizabeth R. Flynn, Jussara M. do Carmo, Zhen Wang, Alexandre A. da Silva, Alan J. Mouton, Ana C. M. Omoto, Michael E. Hall and John E. Hall

Department of Physiology and Biophysics, Mississippi Center for Obesity Research, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, MS, United States

Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfunction and oxidative stress play important roles in progression of HF. This study tested the hypothesis that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves mitochondrial function and reduces reactive oxygen species (ROS) while enhancing cardiac performance through direct effects on the heart in a non-diabetic mouse model of HF induced by transverse aortic constriction (TAC). EMPA or vehicle was administered orally for 4 weeks starting 2 weeks post-TAC. EMPA treatment did not alter blood glucose or body weight but significantly attenuated TAC-induced cardiac dysfunction and ventricular remodeling. Impaired mitochondrial oxidative phosphorylation (OXPHOS) in failing hearts was significantly improved by EMPA. EMPA treatment also enhanced mitochondrial biogenesis and restored normal mitochondria morphology. Although TAC increased mitochondrial ROS and decreased endogenous antioxidants, EMPA markedly inhibited cardiac ROS production and upregulated expression of endogenous antioxidants. In addition, EMPA enhanced autophagy and decreased cardiac apoptosis in TAC-induced HF. Importantly, mitochondrial respiration significantly increased in ex vivo cardiac fibers after direct treatment with EMPA. Our results indicate that EMPA has direct effects on the heart, independently of reductions in blood glucose, to enhance mitochondrial function by upregulating mitochondrial biogenesis, enhancing OXPHOS, reducing ROS production, attenuating apoptosis, and increasing autophagy to improve overall cardiac function in a non-diabetic model of pressure overload-induced HF.

Keywords: empagliflozin, sodium-glucose cotransporter 2, heart failure, mitochondrial biogenesis, reactive oxidative species, apoptosis, autophagy
INTRODUCTION

Although there have been improvements in the treatment and overall prognosis for heart failure (HF), the 5-year mortality rate is still high (1). Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to attenuate cardiac dysfunction and HF mortality in animal models and clinical trials (2–4). However, the mechanisms for cardiac protection by SGLT2 inhibitors are still unclear (5). Previous studies from our laboratory and from others have shown that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves cardiac glucose and fatty acid oxidation, increases cardiac efficiency and improves overall cardiac function after transverse aortic constriction (TAC)-induced HF (6–8). However, the cellular mechanisms by which EMPA increases cardiac oxidative phosphorylation (OXPHOS) in failing hearts and improves cardiac function remain unclear. Mitochondria, the cell “energy factory,” supplies most of the energy needed by the heart. Thus, proper mitochondrial function is essential for maintaining a balance between cardiac energy supply and demand.

In HF, calcium mishandling and excessive oxidative stress can impair electron transport chain in mitochondria, leading to reduced fatty acid oxidation, uncoupling between glycolysis and glucose oxidation, and increased permeability of mitochondrial membranes. Release of reactive oxygen species (ROS), cytochrome C (Cyt C) and mitochondrial DNA (mtDNA) can induce inflammation, trigger apoptosis and result in cell death (9, 10). All these effects may further exacerbate HF. Conversely, clearance of damaged mitochondria through autophagy/mitophagy and attenuation of oxidative stress by endogenous antioxidants play cardioprotective roles in maintaining a healthy mitochondrial population. Thus, in the current study we tested the hypothesis that EMPA treatment may increase mitochondrial biogenesis, upregulate mitochondrial respiration and reduce ROS while favoring autophagy to protect the myocardium against TAC-induced cardiac dysfunction.

MATERIALS AND METHODS

Animals

Male C57Bl/6J mice (3 to 4 months of age) were obtained from the Jackson Laboratory (Bar Harbor, ME). All experimental procedures and protocols conformed to the “Guide for the Care and Use of Laboratory Animals” published by the US National Institutes of Health. The animal protocols were approved by the Institutional Animal Care and Use Committee of University of Mississippi Medical Center. Mice were housed for at least 8 h. Fixed tissues were trimmed to 1 mm3, stained with 10% formaldehyde, buffered, pH 7.4, Carson-Millonig formulation; Visualsonics, Toronto, Canada) was performed to measure cardiac function, including systolic and diastolic parameters.

Body Weight and Fasting Blood Glucose Measurements

Body weight and fasting blood glucose were measured at baseline and at the end of the protocol, respectively. The mice were fasted for 6 h (8:00 a.m. to 2:00 p.m.) and blood glucose levels were determined using a glucose meter (ReliOn, USA).

Echocardiography

Animals from each group were anesthetized with 1–2% isoflurane (inhalation) and transthoracic echocardiography (Vevo 3100, Visualsonics, Toronto, Canada) was performed to measure cardiac function, including systolic and diastolic parameters.

Left Ventricular Pressure-Volume Loop Analysis

At the end of the protocol, left ventricular pressure-volume loop analysis was performed as previously described (12). Briefly, the mice were anesthetized with urethane (1 g/kg, i.p.). After implanting a (RenaPulse tubing, 120 RPT040, Braintree, MA) catheter in the internal jugular vein for hypertonic saline bolus injections, a catheter (Millar 1.4F, SPR 839, Millar Instruments) was inserted into LV through the apex. Hypertonic saline (15% NaCl, 5 μL) was injected to obtain parallel conductance. The following parameters were obtained: heart rate (HR), maximum dP/dt (+dP/dtmax), minimum dP/dt (−dP/dtmin), isovolumetric relaxation time constant (tau), end-diastolic pressure volume relationship (EDPVR), and LV end-diastolic pressure (LVEDP).

Transmission Electron Microscopy

Heart tissues were rapidly immersed in tissue fixative buffer (10% formaldehyde, buffered, pH 7.4, Carson-Millonig formulation; RI31911; Ricca Chemicals, Arlington, TX, USA) at 4°C for at least 8 h. Fixed tissues were trimmed to 1 mm3, stained with OsO4 for 1 h, dehydrated in a graded ethanol series for 10 min per step (once in 35, 50, 70, and 95% and twice in 100% ethanol),
washed twice with acetone for 15 min per wash, washed in a solution of 1:1 acetone:Epon for 1 h, and finally embedded in 100% Epon (Ted Pella, Redding, CA, USA) for 30 min. After incubating at 60°C overnight, the Epon block was semithin sectioned (10–12 1-µm thick sections) by using Sorvall MT-6000-XL (RMC Boeckeler, Tucson, AZ, USA) and a glass knife. Semithin sections were stained with 1% toluidine and observed under a light microscope to locate areas of interest for ultrathin sections. After trimming, the Epon block was thin sectioned (70 nm thick) by using a Leica Reichert Ultracut microtome and diamond knife. Thin sections were then applied on copper grids, air dried, stained with 2% uranyl acetate for 3 min and calcinated lead citrate for 30 s, and rinsed in distilled water by briskly dipping up and down for 30 s. The stained grid was loaded in a Jem-1400 transmission electron microscopy (Jeol, Tokyo, Japan) with an ANT camera system. At least 5 sections from each sample were examined with the transmission electron microscope. Each entire section was thoroughly viewed at low magnifications to find areas of interest and to observe size, shape and arrangement of mitochondria.

**Immunohistochemistry**

Heart paraffin embedded tissue sections (5 µm) were prepared as described previously (11). After they were dewaxed and rehydrated, the sections were treated with 0.1 M sodium citrate buffer for antigen retrieval. Then they were incubated with 10% normal donkey serum for 20 min at room temperature. Sections were then incubated at 4°C overnight with cleaved caspase-3 (Cell Signaling, 14220) (1:500 dilution). Sections were rinsed in PBS and incubated with a horseradish peroxidase (HRP) secondary antibody (Cell Signaling, 8114) in block solution (1:500 dilution) and DAB (3,3'-diaminobenzidine) (Cell Signaling, 8059) at room temperature. Following PBS rinse, sections were counterstained sections with hematoxylin (Cell Signaling, 8059) at room temperature. Following PBS rinse, sections were incubated at 4°C overnight with cleaved caspase-3 (Cell Signaling, 14220) (1:500 dilution). Sections were rinsed in PBS and incubated with a horseradish peroxidase (HRP) secondary antibody (Cell Signaling, 8114) in block solution (1:500 dilution) and DAB (3,3'-diaminobenzidine) (Cell Signaling, 8059) at room temperature. Following PBS rinse, sections were counterstained sections with hematoxylin (Cell Signaling, 14166). Finally, these sections were observed under the light microscope.

**Mitochondrial/Cytosol Fractionation**

The separation of mitochondria and cytosol in hearts was performed following the protocol detailed by the manufacturer (Abcam, ab65320).

**Immunofluorescence Staining**

The cardiac sections for immunofluorescence staining were prepared as described for immunohistochemistry. Then, the sections were incubated at 4°C overnight following addition of Cyt C (1:500, Cell Signaling, 12963) and IraZolve-Mito (1:1000, Cayman, 25910). Subsequently, samples were washed three times and incubated with fluorescent secondary antibodies (goat anti-rabbit IgG, 1:500, Alexa Fluor® 555, A32732) at room temperature for 2 h in the dark wet chamber. Samples were washed with PBS, stained with DAPI for 5 min at room temperature, mounted, and then observed under fluorescence microscope.

**Masson and Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Staining**

Masson trichrome stain (Sigma-Aldrich) and TUNEL staining (Cell Death Detection Kit, Roche, 11684809910) were performed following the protocol detailed by the manufacturer.

**Immunoblotting**

Immunoblotting was performed as previously described (13–15). Briefly, protein concentration was measured using the Bradford dye-binding method (Dye Reagent Concentrate, Bio-Rad Protein Assay). The target proteins were separated by SDS-PAGE and transferred to Millipore nitrocellulose membranes (BioRad, Hercules, CA). The membranes were incubated with primary antibodies at 4°C overnight. Then, membranes were incubated with secondary antibodies at room temperature for 1 h and signal intensity was determined using the Odyssey Infrared Imaging System (LI-COR, Lincoln, NE).

Antibodies against phospho-AMP-activated protein kinase (p-AMPK) (Cell Signaling, 2535), AMPK (Cell Signaling, 5831), phospho-mammalian target of rapamycin (p-mTOR) (Cell Signaling, 2971), mTOR (Cell Signaling, 2983), phospho-Unc-51 like autophagy activating kinase (p-Ulk1) (Cell Signaling, 14202), Ulk1 (Cell Signaling, 8054), autophagy related 7 (Atg7) (Cell Signaling, 8558), Beclin1 (Novus, NB500-249), light chain 3 (LC3) A/B (Cell Signaling, 4108), Bcl-2 (Cell Signaling, 3498), Bax (Cell Signaling, 14796), cleaved caspase-3 (Cell Signaling, 9664), phospho-extracellular signal-regulated kinase (p-ERK) (Cell Signaling, 4370), ERK (Cell Signaling, 4695), phospho-Bad (Cell Signaling, 9291), Bad (Cell Signaling, 9292), nuclear respiratory factor 1 (NRF-1) (Novus, NPBP2-75597), the nuclear factor erythroid 2-related factor 2 (NRF-2) (Novus, H00004780-M02), heme oxygenase-1 (HO-1) (Cell Signaling, 86806), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) (Novus, NB1-04676), mitochondrial transcription factor A (TFAM) (Novus, NPBP2-19437), cyclooxygenase1 (COX1) (Cell Signaling, 9896), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling, 2118), were used as primary antibodies. IRDye® 800CW Donkey anti-Rabbit IgG (LI-COR, 925-32213) and IRDye® 680RD Donkey anti-Rabbit IgG (LI-COR, 925-68073) were used as secondary antibodies.

**Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)**

Total RNA was isolated from heart tissues using Trizol reagent (Invitrogen,15596026) and real-time qPCR was performed as previously described (14). RT-qPCR was performed in a 10 µL reaction mixture prepared with SYBR GREEN PCR Master Mix (Applied Biosystems, Warrington, UK) containing an appropriately diluted cDNA solution and 0.2 mM of each primer at 95°C for 10 min, followed by 35 cycles at 95°C for 10 s and 60°C for 45 s. All reactions were conducted in triplicate, and data were analyzed using the delta Ct (ΔΔCt) method. These transcripts were normalized to β-actin. The details of primers are shown in Table 1.
Mitochondrial Respiration Rate Analysis
A high-resolution respirometer (Oxygraphy2k, Oroboros Instruments GmbH) was equipped with a two-channel fluorescence optical module to simultaneously monitor oxygen concentration and \( \text{H}_2\text{O}_2 \) production as previously described (16, 17) with a data collection interval of 0.2 s. \( \text{H}_2\text{O}_2 \) release was measured from the fluorescence of resorufin formed from Amplex UltraRed reacting with \( \text{H}_2\text{O}_2 \) in the presence of horseradish peroxidase. Oxygen polarography was performed at 37°C in O2k-chambers. Oxygen concentration and oxygen flux per tissue mass were recorded real-time using DatLab software. Malate (0.5 mM) and glutamate (10 mM), ADP (2.5 mM), succinate (10 mM), retenone (10 µM) and antamycin (5 µM) were added into the chambers sequentially.

Statistical Analysis
Data were expressed as mean ± standard error of the means (SEM). Two-tailed Student’s \( t \) test was used for two-group comparisons, while one-way or two-way ANOVA with Tukey’s post hoc tests were used for multiple group comparisons (Prism 7.0, GraphPad Software, La Jolla, CA). A \( p \)-value of <0.05 was considered statistically significant.

RESULTS
EMPA Attenuated Cardiac Remodeling After TAC Without Changing Fasting Blood Glucose
Consistent with our previous findings, EMPA did not alter fasting blood glucose (FBG) or body weight in any of the different groups of mice (Table 2) (7). However, EMPA significantly attenuated TAC-induced cardiac hypertrophy (Figure 1A, left panel). Left

### TABLE 1 | RT-qPCR primers.

| Gene     | Species | Forward                                      | Reverse                                      |
|----------|---------|----------------------------------------------|----------------------------------------------|
| Atg7     | Mouse   | 5’-CTTGTGAAGTGGATCAAAGGC-3’                  | 5’-GACGAAAGGACCAAGACAGTG-3’                 |
| Beclin1  | Mouse   | 5’-GGCAATAAGATGGGCTGA-3’                     | 5’-GCTGACACAGTGCAGAAA-3’                    |
| Catalase | Mouse   | 5’-TTGTTGGCTTGGTCACTGTGTTAG-3’               | 5’-GACGCGAAAGGACCAAGACAGTG-3’               |
| COX1     | Mouse   | 5’-ATCAACTACGCAGTATCGACG-3’                  | 5’-CCTCAGGTCGGATAGAAGA-3’                   |
| GAPDH    | Mouse   | 5’-GCTGCTCTTGAGACTTCTA-3’                    | 5’-TGTCAGGGTTCTCTTCCTCC-3’                  |
| GCLM     | Mouse   | 5’-GACGAGATCCTGAGTTGATTT-3’                  | 5’-TGGAGCTTTACAGCCATTGC-3’                  |
| HO-1     | Mouse   | 5’-GACACCTTGGAGAATGTGTT-3’                   | 5’-GGGTATTGTCGAACTGACC-3’                   |
| LC3      | Mouse   | 5’-GACGAGATCCTGAGTTGATTT-3’                  | 5’-TGGAGCTTTACAGCCATTGC-3’                  |
| NRF-1    | Mouse   | 5’-GACACCTTGGAGAATGTGTT-3’                   | 5’-GGGTATTGTCGAACTGACC-3’                   |
| NRF-2    | Mouse   | 5’-GACGAGATCCTGAGTTGATTT-3’                  | 5’-TGGAGCTTTACAGCCATTGC-3’                  |
| PGC1α    | Mouse   | 5’-AAACTTGCTAGCGGTCCTCA-3’                   | 5’-TGGCTGGTGCCAGTAAGG-3’                    |
| TFAM     | Mouse   | 5’-TTGCTGGCTAACGATCGTTCT-3’                  | 5’-AAAGGCTGAGAAGCGATA-3’                    |

### TABLE 2 | Body weight and fasting blood glucose in different groups.

|                     | Sham       | Sham + EMPA | TAC         | TAC + EMPA |
|---------------------|------------|-------------|-------------|------------|
| Body weight (g)     |            |             |             |            |
| Baseline            | 27.7 ± 0.5 | 27.1 ± 0.4  | 29.6 ± 1.2  | 28.1 ± 0.8 |
| 6 weeks             | 29.4 ± 0.4 | 28.2 ± 0.5  | 30.1 ± 0.8  | 28.0 ± 1.0 |
| FBG (mg/dL)         |            |             |             |            |
| Baseline            | 91.7 ± 4.2 | 106.2 ± 8.2 | 94.3 ± 6.2  | 89.9 ± 3.4 |
| 6 weeks             | 98.8 ± 8.6 | 101.7 ± 6.0 | 115.5 ± 5.1 | 107.7 ± 9.7 |

Results are expressed as mean ± SEM. One-way ANOVA and Tukey post hoc test. FBG, fasting blood glucose; EMPA, empagliflozin; TAC, transverse aortic constriction; SEM, standard error of the mean.
ventricular (LV) mass increased by 68.9% after TAC and this increase was substantially attenuated by EMPA (Figure 1A, middle panel). TAC-induced increases in collagen deposition, indicated by Masson staining, were reduced by 54.2% with EMPA treatment (Figure 1A, right panel).

**EMPA Attenuated Cardiac Systolic and Diastolic Dysfunction After TAC**

Transthoracic echocardiography measurements of EF and FS were reduced 55.3% and 60.1%, respectively, after TAC and these changes were markedly attenuated by EMPA treatment, suggesting improvements of cardiac systolic function. TAC caused 85.9% and 100.6% elevations in IVRT and MPI, respectively, compared to the sham group and these changes were also largely reversed in mice treated with EMPA (Figure 1B).

In order to directly measure ventricular pressure and cardiac function *in vivo*, we inserted a Millar catheter into the LV though the apex. We assessed cardiac systolic function in these mice by LV pressure at end systole (LVESP) and +dP/dt max. Diastolic function was accessed by –dP/dt max and Tau and ventricular stiffness by end diastolic pressure volume relationship (EDPVR). Although EMPA did not reduce the elevation in LVESP after TAC, it markedly reduced Tau and EDPVR, suggesting improvement of diastolic function and increased compliance of the LV (Figure 1C).

**EMPA Reduced Intracellular ROS and Increased Endogenous Antioxidant After TAC**

We measured oxygen consumption and H$_2$O$_2$ production in LV muscle fibers from different groups (Figure 1D). The results showed that both basal and maximum oxygen consumption rates (OCR) were reduced after TAC, while basal and maximum H$_2$O$_2$ production were increased. However, EMPA treatment increased OCR and attenuated H$_2$O$_2$ production at basal and maximal conditions after TAC.

To measure production of superoxide, isolated cardiomyocytes were stained with Mitosox red. After 6 weeks of TAC, cardiomyocyte production of superoxide was significantly increased compared to sham group, however, EMPA treatment reduced superoxide in these cells by 44.4% (Figure 2A).

Cardiac expression of endogenous antioxidant-related genes was significantly reduced after TAC (Figures 2B,C). Protein and mRNA levels of NRF-2 and HO-1 were decreased after TAC. Also, the important antioxidant catalase and glutamate-cysteine ligase modifier subunit (GCLM) were downregulated in hearts of the TAC group. EMPA treatment restored cardiac expression of HO-1 and NRF-2 proteins after TAC. However, the mRNA levels of NRF-2, HO-1, catalase and GCLM were not changed after EMPA treatment.

**EMPA Enhanced Mitochondrial Biogenesis After TAC**

TEM clearly showed that mitochondrial number in LV cardiomyocytes was significantly reduced after TAC compared to the sham group (Figure 3A). Moreover, the mean mitochondrial area was also significantly smaller than in the sham group. EMPA treatment in TAC mice increased cardiomyocyte mitochondrial number and mean area (Figure 3A).

To determine how EMPA affected mitochondrial biogenesis in hearts after TAC, the expressions of PGC1α, NRF-1 and TFAM, which are involved in mitochondrial biogenesis, were investigated by immunoblotting and RT-qPCR (Figures 3B,C). The results showed that EMPA treatment increased expression of PGC1α, NRF-1 and TFAM after TAC. Furthermore, EMPA increased expression of COX1, also suggesting that EMPA increased mitochondrial count in TAC mice.

**EMPA Reduced Apoptosis and Cyt C Release From Mitochondria to Cytosol After TAC**

The number of TUNEL positive cells as well as expression of cleaved caspase-3 in the LV were significantly increased after TAC indicating increased apoptosis. However, EMPA treatment attenuated the percentage of TUNEL positive cells and expression of cleaved caspase-3 in LVs of TAC mice (Figures 4A,B). To investigate how EMPA regulates cardiac apoptosis, the ERK-Bad pathway was assessed by immunoblotting. As shown in Figure 4C, TAC reduced phosphorylation of ERK and Bad, Bcl-2, but increased Bax and cleaved caspase-3. Conversely, EMPA restored the p-ERK/ERK and p-Bad/bad, reduced cleaved caspase-3 and Bax/Bcl-2 ratio.

Due to mitochondrial dysfunction, mitochondrial outer membrane permeabilization may be changed (20). Thus we separated the mitochondria from cytosol, and found that Cyt C was released from cardiac mitochondria into the cytosol in the TAC group. However, EMPA reduced the release of Cyt C from mitochondria after TAC (Figures 4D,E).

**EMPA Improved Autophagy in Hearts After TAC**

TEM images showed that the number of autophagosomes in the TAC + EMPA group was larger than in other groups (Figure 5A). Additionally, the autophagy-related signal pathway was investigated by immunoblotting. The results showed that phosphorylation of AMPK, mTOR and Ulk was reduced after TAC, but restored by EMPA treatment. Also, the Beclin1, Atg7 and ratio of LC3 II/I were decreased after TAC. However, EMPA treatment increased cardiac expression of Beclin1 and Atg7, and increased the LC3 II/I ratio. Furthermore, RT-qPCR results showed that the mRNA levels of Atg7 and LC3 were reduced after TAC but increased by EMPA treatment. However, the mRNA level of Beclin1 was not different among these groups (Figures 5B,C).

**Acute EMPA Treatment Increased Cardiac Mitochondrial Respiration and Reduced Hydrogen Peroxide Production in Isolated Cardiac Muscle Fibers From Failing Hearts**

To investigate whether EMPA has direct effects on the heart, we divided the muscle fibers of the LV from the TAC group into two parts: tissues treated with EMPA (1.0 mM) or vehicle
**FIGURE 1** | EMPA treatment attenuated remodeling of the LV, improved cardiac function and increased mitochondrial respiration. (A) Left, Masson staining of cross sections of hearts and Right (the collagen fibers were stained blue), quantitative analysis of left ventricle (LV) mass and heart collagen volume. (B) Transthoracic echocardiography showed the ejection fraction (EF), fraction shortening (FS), isovolumetric relaxation time (IVRT) and myocardial performance index (MPI) of hearts from different groups. (C) Cardiac function assessed by direct intraventricular pressure measurements. (D) Mitochondrial respiration and peroxide production in hearts from different groups. Original magnification $\times 100$, Results are expressed as mean $\pm$ SEM, $n = 5–7$, *$p < 0.05$ vs. corresponding sham group, †$p < 0.05$ vs. corresponding TAC vehicle group. One-way ANOVA and Tukey post hoc test. EMPA, empagliflozin; SEM, standard error of the mean; TAC, transverse aortic constriction; LV, left ventricle; HR, heart rate; EDPVR, end diastolic pressure volume relationship; LVESP, left ventricular end-systolic pressure; OCR, oxygen consumption rate.

for 1 h before placing them into the Oxygraphy2K chambers with EMPA (1.0 mM) or vehicle. The results showed that acute EMPA treatment, similar to the effects of chronic treatment, significantly increased baseline and maximal OCR, and reduced basal and maximal peroxide production compared to vehicle groups (Figures 6A,B).

**DISCUSSION**

The beneficial effects of SGLT2 inhibitors in treating HF have been documented in several clinical trials (2, 21). However, the mechanisms by which SGLT2 inhibitors protect the heart in HF are still controversial. Although
our previous study demonstrated that EMPA, a highly selective SGLT2 inhibitor, may have direct effects in the heart to improve glucose and fatty acid oxidation and increase ATP production in HF (7), the mechanisms involved remain unclear. To further investigate how EMPA regulates cardiac metabolism, we focused on the mitochondria since they are the “powerhouses” of the cells and HF is associated with impaired mitochondrial function. Our results indicate that EMPA can enhance mitochondrial function by upregulating mitochondrial biogenesis, enhance OXPHOS, reduce ROS production, attenuate apoptosis, and increase autophagy to improve overall cardiac function in pressure overload-induced HF.

EMPA Treatment Attenuated LV Hypertrophy and Fibrosis After TAC
Cardiac hypertrophy and fibrosis are independent risk factors for development of HF (22). Our results, in line with others, showed that SGLT2 inhibitors can induce LV mass regression in HF (23, 24). Although Byrne et al. reported that EMPA prevents worsening of cardiac function induced by TAC (8), they did not find obvious improvement of cardiomyocyte hypertrophy after EMPA treatment. One possible mechanism that has been proposed for the anti-hypertrophic effect of SGLT2 inhibitors is the blood pressure-lowering effect (25). However, this effect is mild. We did not observe obvious reductions in intraventricular or systemic pressure in TAC.
EMPA and Mitochondria in HF

EMPA treatment increased mitochondrial biogenesis. (A) Left, Transmission electron microscopy showing the morphology of mitochondria in sham, sham + EMPA, TAC and TAC + EMPA groups and Right, quantitative analysis of mitochondrial size and counts. Results are expressed as mean ± SEM, n = 3–5, *p < 0.05 vs. corresponding sham, †p < 0.05 vs. corresponding TAC.

(B) Left, Representative blots of mitochondrial biogenesis-related proteins and Right, quantitative results. (C) Relative mRNA levels of PGC1α, NRF1, TFAM and COX1. Results are expressed as mean ± SEM, n = 5–7, *p < 0.05 vs. corresponding sham group, †p < 0.05 vs. corresponding TAC vehicle group. One-way ANOVA and Tukey post hoc test. EMPA, empagliflozin; SEM, standard error of the mean; TAC, transverse aortic constriction; PGC1-α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; NRF-1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; COX1, cyclooxygenase1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

+ EMPA groups compared to the TAC group. It is known that mTORC1 plays an important role in protein synthesis, cellular proliferation and metabolism (26, 27), and prolonged and excessive activation of mTORC1 can cause cardiac hypertrophy (28). EMPA may inhibit mTORC1’s activity through AMPK (the mechanism by which EMPA activates AMPK will be discussed later), preventing the formation of the complex (29, 30). In addition, EMPA can upregulate expression of Sestrin2, a stress-induced protein, which can directly inhibit activation of mTORC1. Thus, EMPA may attenuate cardiac hypertrophy by inhibiting mTORC1 to decrease protein synthesis in hearts.

EMPA also reduced cardiac fibrosis in TAC-induced HF. Other SGLT2 inhibitors, e.g. dapagliflozin and canagliflozin, can also reduce tissue fibrosis (31). Since SGLT2 is mainly expressed in kidneys, but not in cardiomyocytes or cardiac...
EMPA Treatment Improved Mitochondrial Biogenesis and Reduced ROS Generation in TAC-Induced HF

An important finding of the present study is that EMPA treatment for four weeks significantly increased mitochondrial numbers and reduced cellular ROS in hearts exposed to chronic TAC. One potential mechanism of improved mitochondrial biogenesis is activation of the PGC1α/NRF-1 pathway by EMPA.
FIGURE 5 | EMPA treatment enhanced autophagy in failing hearts. (A) Transmission electron microscopy (TEM) showed autophagosomes in the hearts. Red arrows point to autophagosomes. (B) EMPA activated autophagy pathway by inhibiting mTOR pathway. (C) RT-PCR results showed that the mRNA expression of Beclin1, Atg7 and LC3 were increased by EMPA treatment after TAC. Results are expressed as mean ± SEM, n = 5–7, *p < 0.05 vs. corresponding sham group, †p < 0.05 vs. corresponding TAC vehicle group. One-way ANOVA and Tukey post hoc test. EMPA, empagliflozin; SEM, standard error of the mean; TAC, transverse aortic constriction; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; Ulk, Unc-51 like autophagy activating kinase; Atg7, autophagy related 7; LC3, light chain 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

PGC1α is a transcriptional coactivator that is considered to be a critical inducer of mitochondrial biogenesis in cells (35, 36). SGLT2 inhibitors treatment may induce a fasting-like paradigm, leading to the activation of PGC1α pathway (37). Our results are consistent with this hypothesis since EMPA treatment substantially increased cardiac expression of PGC1α and NRF-1 in TAC-induced HF.

The anti-oxidation effects of EMPA are impressive. Both basal and maximum H2O2 production were significantly reduced by chronic EMPA treatment in failing hearts. Additionally, EMPA treatment decreased superoxide in cardiomyocytes from TAC groups.

To investigate how EMPA regulates endogenous antioxidants, the NRF-2/HO-1 pathway was evaluated. NRF-2 is a transcription factor responsible for maintenance of cellular redox homeostasis and phase II detoxification responses in mammals (38), and NRF-2/antioxidant response element (ARE) signaling is an important antioxidant pathway involved in the defense against oxidative stress (35, 36). HO-1 is one of the ARE-regulated phase II detoxifying enzymes regulated by NRF-2, which provides robust protection against oxidative stresses (37).

Our results show that EMPA increased the protein levels of NRF-2 and HO-1 after TAC. However, EMPA did not change mRNA levels of NRF-2, HO-1, catalase and GCLM. These results
suggest that EMPA may reduce degradation of these proteins rather than increase their translation, although the detailed mechanisms responsible for increased levels of NRF-2 and HO-1 are uncertain and require further investigation.

**EMPA Enhances Cardiac Autophagy and Reduces Apoptosis of Cardiomyocytes**

Autophagy is an adaptive response of cells to stress. It can recycle damaged mitochondria and other organelles for the resynthesis of new organelles and ATP (39). Impaired autophagy increases susceptibility of the heart to stresses and promotes HF (40, 41). EMPA partially restored activity of AMPK and inhibited mTOR, which could then enhance autophagy in LV cardiomyocytes. Furthermore, autophagy also plays an important role in maintaining cellular ROS homeostasis by eliminating oxidized peroxisomes (42), which provides a clue to the mechanism by which EMPA attenuates ROS production in failing hearts.

Mitochondrial dysfunction and overproduced ROS can cause cellular apoptosis by increasing permeabilization of mitochondrial outer membranes and releasing Cyt C from mitochondria into the cytosol, thus activating caspase and apoptosis (43). However, we found that EMPA increased phosphorylation of ERK and Bad, upregulated Bcl-2, and reduced Bax expression in hearts exposed to TAC. It is known that activated ERK can phosphorylate Bad at Ser112 through p90 ribosomal S6 kinase (RSK) (44), and then convert Bcl-2 into an activated form, preventing pore formation in the mitochondrial outer membrane and Cyt C release, as a result reducing cellular apoptosis (45). Thus, EMPA treatment may reduce Cyt C release and attenuate myocardial apoptosis in TAC-induced HF via the ERK/Bad pathway.

**EMPA Acts Directly on the Heart to Improve Mitochondrial Respiration**

Although we demonstrated that EMPA can improve mitochondrial respiration in HF, there is still a question of whether the improvements of mitochondrial function by EMPA result from direct effects on the heart. As shown in Figure 5, incubating LV muscle fibers from TAC hearts with EMPA increased the OCR and reduced H₂O₂ production, indicating that EMPA has direct cardiac effects. Our previous study suggested that EMPA may directly bind glucose transporters, inhibit excessive glycolysis and improve glucose oxidation and fatty acid oxidation (7). In addition, we also demonstrated that EMPA can directly activate the AMPK pathway in the heart (6), and activated AMPK is known to enhance autophagy, reduce apoptosis, decrease ROS production and increase mitochondrial biogenesis (18, 46, 47). EMPA may activate AMPK through liver kinase B1 (LKB1) and/or by increasing Sestrin2 (6, 48). Furthermore, EMPA may suppress Drp1 phosphorylation at Ser616, and increase Drp1 phosphorylation at Ser637, leading to inhibition of mitochondrial fission by triggering the AMPK pathway, ultimately improving cardiac mitochondrial function (49).

**Limitations**

Although the present study demonstrates that EMPA has multiple direct effects on cardiomyocytes that improve mitochondrial respiration and energy metabolism, our findings do not rule out the possibility that systemic effects of EMPA can also contribute to overall improvement of cardiac function in pressure overload-induced HF. Previous studies have provided evidence that multiple systemic effects of SGLT2 inhibition, including decreased blood pressure, natriuresis, glycosuria, decreased extracellular fluid volume, and improved kidney function, may provide beneficial cardiovascular effects in patients with HF, with or without diabetes (5, 50). However, observations from other studies (5, 50), coupled with our findings of improved cardiac mitochondrial function and energy metabolism in ex vivo cardiomyocytes, make it unlikely that all of EMPA’s beneficial effects in the TAC-induced model of HF can be explained by reductions in blood pressure and other systemic actions.
Although all of the mice used in this study were male, our preliminary data showed that female mice exhibit similar results. Potential sex differences during EMPA treatment in HF should be further investigated in future studies.

**CONCLUSIONS AND PERSPECTIVES**

Our results indicate that SGLT2 inhibition with EMPA increases cardiac mitochondrial biogenesis, reduces ROS production, decreases myocardial apoptosis, enhances autophagy, and activates the AMPK-mTOR pathway, thus improving cardiomyocyte mitochondrial function after TAC-induced HF (Figure 7). These protective functions of EMPA occur by direct cardiac effects and contribute to improved systolic and diastolic function in a non-diabetic model of HF induced by pressure overload.

The mechanisms by which EMPA binds to cardiac cells and exerts its protective effects have not been fully elucidated. However, we recently provided evidence from molecular docking analysis and isolated perfused heart studies suggesting that EMPA can bind cardiac glucose transporters to reduce cardiac glycolysis and rebalance coupling between glycolysis and oxidative phosphorylation. These direct cardioprotective effects of EMPA, which improve mitochondrial function and occur independently of reductions in blood glucose or diuresis, highlight the potential beneficial effects SGLT2 inhibitors in other conditions associated with mitochondrial dysfunction, such as myocardial toxicity associated with chemotherapeutics.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by University of Mississippi Medical Center.

**AUTHOR CONTRIBUTIONS**

XL and JH designed the study, conducted the research, and wrote the article. EF, JC, ZW, AS, AM, AO, and MH contributed to the revision of the article for important content, prepared the figures, and helped to analyze and interpret the data. All authors have read and approved the final version of the article.

**FUNDING**

This work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) [Grant Number P01HL051971], the National...
REFERENCES

1. Taylor CJ, Ordonez-Mena JM, Rosalie AK, Lay-Flurrie S, Jones NR, Marshall T. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. (2019) 364:l223. doi: 10.1136/bmj.l223

2. McMurray JVF, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. (2019) 381:1995–2008. doi: 10.1056/NEJMoa1911303

3. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. (2020) 383:1413–24. doi: 10.1056/NEJMoa2022190

4. Yurista SR, Siljé HHFW, Oberdorfer-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL. Sodium-glucose co-transporter 2 inhibitor and empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. (2019) 21:862–73. doi: 10.1002/ejhf.1473

5. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. (2020) 5:632–44. doi: 10.1016/j.jactbs.2020.02.004

6. Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D. Empagliflozin attenuates cardiac sodium/glucose co-transporter 2 (SGLT2) overexpression in aortic area. Biomolecules. (2021) 11:493. doi: 10.3390/biom11050493

7. Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. (2021) 10:e018298. doi: 10.1161/JAHA.120.018298

8. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Mason G. Sodium-glucose co-transporter 2 (SGLT2) inhibition with empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. (2021) 10:e018298. doi: 10.1161/JAHA.120.018298

9. Bernardi P, Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J Mol Cell Cardiol. (2015) 78:100-6. doi: 10.1016/j.yjmcc.2014.09.023

10. Paneni F, Costantino S, Hamdani N. Regression of left ventricular hypertrophy with SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. (2018) 114:12–8. doi: 10.1093/cvr/cvx149

11. Braunwald E. The war against heart failure: The Lancet lecture. Lancet. (2015) 385:812–24. doi: 10.1016/S0140-6736(14)61889-4

12. Panzer H, Alhadeff A, Alhadeff J, Alhadeff B, Alhadeff B. SLC5A1 expression and function in the heart. J Physiol. (2015) 593:6333–45. doi: 10.1113/jphysiol.2015.304097

13. Zorov DB, Juhászova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. (2014) 94:909–50. doi: 10.1152/physrev.00026.2013

14. Cates C, Rousselle T, Wang J, Quan N, Wang L, Chen X. Activated protein C protects against pressure overload-induced hypertrophy through AMPK signaling. Biochem Biophys Res Commun. (2018) 495:2584–94. doi: 10.1016/j.bbrc.2017.12.125

15. Morrison A, Chen L, Wang J, Zhang M, Yang H, Ma Y, et al. Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB J. (2015) 29:408–17. doi: 10.1096/fj.14-258814

16. Stepanova A, Kahl A, Konrad C, Ten V, Starkov AS, Galkin A. Reverse electron transfer results in a loss of flavin from mitochondrial complex I. Potential mechanism for brain ischemia reperfusion injury. J Cereb Blood Flow Metab. (2017) 37:5649–58. doi: 10.1038/jcbf.2017.73

17. Puma LCL, Hedges M, Heckman JM, Mathias IA, Engstrom MR, Brown AB, et al. Experimental oxygen concentration influences rates of mitochondrial hydrogen peroxide release from cardiac and skeletal muscle preparations. Am J Physiol Regul Integr Comp Physiol. (2020) 318:R972–80. doi: 10.1152/ajpregu.00227.2019

18. Ma Y, Li J. Metabolic shifts during aging and pathology. Compr Physiol. (2015) 5:667–86. doi: 10.1002/cphv.c14001

19. Jain RLM. Isolation, culture, and functional analysis of adult mouse cardiomyocytes. Methods Mol Biol. (2007) 139:251–62. doi: 10.1007/978-1-59745-4401963

20. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. (2006) 13:1396–402. doi: 10.1038/sj.cdd.4401963

21. Baragetti P, Pratesi Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. (2018) 114:12–8. doi: 10.1093/cvr/cvx149

22. Braunwald E. The war against heart failure: The Lancet lecture. Lancet. (2015) 385:812–24. doi: 10.1016/S0140-6736(14)61889-4

23. Brown AJM, Gandy S, McCorminn R, Houston GJ, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. (2020) 41:3421–32. doi: 10.1093/eurheartj/ehaa419

24. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Connolly. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. (2019) 140:1693–702. doi: 10.1161/CIRCULATIONAHA.119.042375

25. Paneni F, Costantino S, Hamdani N. Regression of left ventricular hypertrophy with SGLT2 inhibitors. Eur Heart J. (2020) 41:3433–6. doi: 10.1093/eurheartj/ehaa530

26. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. (2013) 126( Pt 8):1713–20. doi: 10.1242/jcs.125773

27. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. (2011) 12:21–35. doi: 10.1038/nrm3025

28. Xie H, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol. (2011) 106:1173–91. doi: 10.1007/s00395-011-0222-8

29. Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, Catalucci D. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest. (2010) 120:2805–16. doi: 10.1172/JCI43008

30. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. (2003) 115:577–90. doi: 10.1016/S0092-8674(03)00929-2

31. Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzl A, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects.

ACKNOWLEDGMENTS

We thank Jingwen Zhang (University of South Florida) for technical support on immunofluorescence and Xuemeng Dai and Sydney P. Moak (University of Mississippi Medical Center) for assistance with Oroboros and Histology.
of SGLT2 inhibitors in diabetic kidney disease. *Diabetologia*. (2019) 62:1154–66. doi: 10.1007/s00125-019-4859-4
32. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. *Curr. Genomics*. (2007) 8:113–28. doi: 10.2174/138920207780368187
33. Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα1/AMPKα2/TGF-beta/Smad signalling in type 2 diabetic rats. *J Cell Mol Med.* (2021) 25:7642–59. doi: 10.1111/jcmm.16601
34. Li C, Zhang J, Xue M, Li X, Han F, Liu X. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. *Cardiovasc Diabetes*. (2019) 18:15. doi: 10.1186/s12933-019-0816-2
35. Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα1/AMPKα2/TGF-beta/Smad signalling in type 2 diabetic rats. *J Cell Mol Med.* (2021) 25:7642–59. doi: 10.1111/jcmm.16601
36. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim Biophys Acta*. (2011) 1813:1269–78. doi: 10.1016/j.bbamcr.2010.09.019
37. Packer M. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. *J Diabetes Complications*. (2020) 34:107647. doi: 10.1016/j.jdiacomp.2020.107647
38. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. *Am J Physiol Heart Circ Physiol.* (2011) 301:H2181–90. doi: 10.1152/ajpheart.00554.2011
39. Wu NN, Tian H, Chen P, Wang D, Ren J, Zhang Y. Physical exercise and selective autophagy: benefit and risk on cardiovascular health. *Cells*. (2019) 8:1436. doi: 10.3390/cells8111436
40. Abdellatif M, Sedej S, Carmona-Gutierrez D, Madeo F, Kroemer G. Autophagy in cardiovascular aging. *Circ Res.* (2018) 123:803–24. doi: 10.1161/CIRCRESAHA.118.312208
41. Schiattarella GG, Hill JA. Therapeutic targeting of autophagy in cardiovascular disease. *J Mol Cell Cardiol.* (2016) 95:86–93. doi: 10.1016/j.yjmcc.2015.11.019
42. Yamauchi S, Mano S, Oikawa K, Hikino K, Teshima KM, Kimori Y, et al. Autophagy controls reactive oxygen species homeostasis in guard cells that is essential for stomatal opening. *Proc Natl Acad Sci U S A*. (2019) 116:19187–92. doi: 10.1073/pnas.1901886116
43. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. *Nat Clin Pract Cardiovasc Med.* (2006) 3:490–8. doi: 10.1038/ncpcardio0583
44. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. *IUBMB Life*. (2006) 58:621–31. doi: 10.1080/15216540600957438
45. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. *Mol Cell*. (2001) 8:705–11. doi: 10.1016/S1097-2765(01)00320-3
46. Qi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic heart. *Trends Endocrinol Metab.* (2015) 26:422–9. doi: 10.1016/j.tem.2015.05.010
47. Ren D, Quan N, Fedorova J, Zhang J, He Z, Li J. Sestrin2 modulates cardiac inflammatory response through maintaining redox homeostasis during ischemia and reperfusion. *Redox Biol.* (2020) 34:101556. doi: 10.1016/j.redox.2020.101556
48. Sun X, Han F, Lu Q, Li X, Ren D, Zhang J. Empagliflozin Ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. *Diabetes*. (2020) 69:1292–305. doi: 10.2337/db19-0991
49. Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. *Redox Biol*. (2018) 15:335–46. doi: 10.1016/j.redox.2017.12.019
50. Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. *J Am Coll Cardiol*. (2020) 75:435–47. doi: 10.1016/j.jacc.2019.11.036

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Flynn, do Carmo, Wang, da Silva, Mouton, Omoto, Hall and Hall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.